Verification of Decreased Basal and Stimulated Serum Pepsinogen-I Levels Is a Useful Non-Invasive Method for Determining the Success of Eradication Therapy forHelicobacter pylori
Authors:
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 31 (2) , 103-110
Abstract
Background: We wanted to demonstrate the effect of Helicobacter pylori eradication on basal and stimulated pepsinogen-I levels in duodenal ulcer patients and to verify whether modification of such levels is a useful method for determining the success of eradication therapy. Methods: Thirty-two patients (24 men; mean age, 45 years) with active duodenal ulcer were studied. In all patients three biopsy specimens were taken from the duodenal bulb, gastric antrum, body, and fundus for microbiologic and histologic examination. Triple therapy consisting of bismuth, metronidazole, and tetracycline was administered. Endoscopy was repeated 1 month after completing therapy, and biopsy specimens were again taken from the gastric antrum and body. Serum samples were taken at initial and repeat endoscopies, to measure basal and stimulated (120 min) pepsinogen-I levels after injection of pentagastrin. Results: H. pylori was eradicated in 26 patients (81%). Significant histologic improvement, in both the antrum and body, was observed (P < 0.001). Basal pepsinogen-I levels (mean and 95% confidence interval) at diagnosis and after eradication were 106 (92–119) and 87 (74–100) ng/ml, respectively (P < 0.001). Similarly, stimulated pepsinogen-I levels (integrated values) decreased from 4790 (4199–5381) before therapy to 3970 (3383–4557) ng/ml · min after eradication (P < 0.001). Pepsinogen I levels did not change in patients in whom H. pylori was not eradicated. The area under the receiver operating characteristic curve for decreased basal and stimulated pepsinogen-I levels was 0.77 (SE, 0.09) and 0.79 (SE, 0.1), respectively. Conclusions: H. pylori eradication in duodenal ulcer patients was associated with a significant decrease in basal and stimulated pepsinogen-I levels. Measurement of these levels could determine how successful response to therapy has been in both the eradication and resolution of associated gastritis. Other advantages of this procedure are that it has low cost and results are evident at an early stage.Keywords
This publication has 33 references indexed in Scilit:
- Influence of Helicobacter pylori, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers.Gut, 1993
- Helicobacterand Hypergastrinemia: The Quisling OptionScandinavian Journal of Gastroenterology, 1991
- Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori.Journal of Clinical Pathology, 1990
- AMOXYCILLIN PLUS TINIDAZOLE FOR CAMPYLOBACTER PYLORI GASTRITIS IN CHILDREN: ASSESSMENT BY SERUM IgG ANTIBODY, PEPSINOGEN I, AND GASTRIN LEVELSThe Lancet, 1989
- Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.Gut, 1988
- The Clinical Significance of Campylobacter pyloriAnnals of Internal Medicine, 1988
- UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATIONThe Lancet, 1984
- SPIRAL BACTERIA OF THE GASTRIC ANTRUMThe Lancet, 1984
- Genetic Heterogeneity of Hyperpepsinogenemic I and Normopepsinogenemic I Duodenal Ulcer DiseaseAnnals of Internal Medicine, 1979
- Duodenal-Ulcer Disease Associated with Elevated Serum Pepsinogen INew England Journal of Medicine, 1979